Neil Schneider, ASA, MAAA
Advertisement
Articles by Neil Schneider, ASA, MAAA
Advertisement
Latest Updated Articles
- Third-Party Validation of Observed Savings From an Oncology Pathways Program
Published: June 18th 2013 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
In CLL, Fixed-Duration Venetoclax Combos Are Equal to Continuous Ibrutinib in Head-to-Head Comparison
2
ASH 2025 Offers Data That Could Make Novel Therapies More Accessible
3
Once-Monthly Maridebart Cafraglutide Shows Up to 16% Weight Loss
4
52-Week VERIFY Data Show Rusfertide Brings Sustained Responses in PV
5
